March 28, 2018 / 5:16 AM / a month ago

BRIEF-Exelixis Says Ipsen received validation of the application for variation to the Cabometyx

March 28 (Reuters) - Exelixis Inc:

* EXELIXIS’ PARTNER IPSEN ANNOUNCES EMA VALIDATION OF THE APPLICATION FOR A NEW INDICATION FOR CABOMETYX® (CABOZANTINIB) FOR PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA

* ‍FILING IS BASED ON RESULTS OF GLOBAL PIVOTAL PHASE 3 CELESTIAL TRIAL, WHICH MET ITS PRIMARY ENDPOINT OF OVERALL SURVIVAL (OS)​

* ‍CABOZANTINIB PROVIDED A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN OS COMPARED WITH PLACEBO​ Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below